Compare Bristol-Myers Squibb Co (BMY) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.53. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| BMY | QDTE | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $36.60 |
52-Week Low | $42.60 | $26.85 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.98, down 1.69% with a bearish technical signal. The ETF employs a weekly covered call strategy on Nasdaq-100 components, generating high distribution yields through 0DTE options. Recent dividend payments show consistent weekly distributions, though the yield has compressed as volatility declined. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
The ETF faces headwinds from declining volatility reducing option premiums, potentially impacting future distribution rates. While the weekly income stream appeals to income investors, the strategy's sustainability depends on market conditions. Current technical weakness suggests near-term pressure, though the high-yield strategy remains attractive for income-focused portfolios in stable markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
